The Pharma Data

JUNE 1, 2022

AstraZeneca’s Chief Executive Officer, Pascal Soriot, today received a British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic in the Queen’s Birthday Honours 2022. This recognition is also theirs and I would like to thank each of them for their commitment to our mission.

Life Science 52

Life Science Medicine Vaccination Vaccine 52

pharmaphorum

AUGUST 11, 2020

Today [11 August 2020], Medicines Discovery Catapult (MDC) announce that it has been awarded government seedcorn funding; provided through UK Research and Innovation’s flagship £236m Strength in Places Fund, along with project partner Cheshire & Warrington Local Enterprise Partnership (LEP).

Medicine 52

Medicine Life Science Development RNA 52

pharmaphorum

OCTOBER 12, 2022

We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. Genomic medicine is a rapidly growing space in which researchers use the information in a person’s genes to identify and administer medical treatment.”.

Genome 89

Genome Genomics Medicine Development 89

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   DS: How are aptamers currently used in the development of precision treatments?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

XTalks

JULY 25, 2022

Later lines of treatment can include monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs). ADCs consist of an antibody attached to a cytotoxin that is delivered to targeted cells. XTALKS WEBINAR: Discussing the Concerns within Clinical Research in Oncology and In-Home Healthcare.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

XTalks

NOVEMBER 4, 2020

It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. They reported their findings last week in the journal Science.

Allergies 98

Allergies Antibody In-Vitro Development 98

Pharma in Brief

DECEMBER 17, 2023

On December 4, 2023, the Federal Court held that a patent claiming a formulation of adalimumab, a monoclonal antibody used to treat autoimmune diseases, is valid and is being infringed by a biosimilar product. The Federal Court upheld the Minister’s decision; AbbVie’s appeal of the Federal Court’s decision is pending (Court File No.

Antibody 52

Antibody Production Regulation Marketing 52

XTalks

AUGUST 22, 2022

Blueprint Medicines announced top-line results from their clinical trial of Ayvakit (avapritinib) in patients with non-advanced systemic mastocytosis (SM) that showed clinically meaningful and highly significant improvements.

Medicine 98

Medicine Clinical Trials Clinical Trials Trials 98

Drug Discovery World

FEBRUARY 19, 2024

Financial landscape In 2023, life science companies experienced a significant decrease in funding, particularly seed funding for early-stage drug development. antibody-drug conjugate [ADC] pipelines in some oncology settings).

Development 59

Development Gene Therapy Drugs Antibody 59

Drug Discovery World

DECEMBER 14, 2023

The new centre represents a flagship investment within the University’s Glasgow Riverside Innovation District (GRID) and will be home to commercial businesses as well as the University of Glasgow-led Living Laboratory for Precision Medicine.

Drugs 75

Drugs Life Science Research Scientist 75

Scienmag

SEPTEMBER 9, 2021

The presence of special immune system defense molecules, called autoimmune antibodies, has been strongly tied to how poorly people fare when hospitalized with COVID-19, a new study shows.

Immune Response 52

Immune Response Life Science Antibody Medicine 52

Drug Discovery World

OCTOBER 20, 2023

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. We aim to continue to ‘open up’ the druggable antibody space.”

Drugs 52

Drugs Antibody DNA Gene Therapy 52

XTalks

FEBRUARY 29, 2024

In a statement , the company said it will discontinue Aduhelm to focus efforts on its other amyloid beta-directed antibody Leqembi (lecanemab) for Alzheimer’s and focus on developing other new treatments. Two years after its approval in 2021 , Biogen has decided to pull the plug on its Alzheimer’s drug Aduhelm (aducanumab).

Drugs 59

Drugs FDA Approval Antibody Life Science 59

Drug Discovery World

FEBRUARY 5, 2024

The launches include an integrated solution suite for liquid biopsy workflows, and the Resolvex i300 and antibody purification columns AffinEx Protein A Capture, adding biomarker discovery, drug development and personalised medicine research to proteomics workflows.

Gene Therapy 64

Gene Therapy Life Science Production Dermatology 64

XTalks

APRIL 17, 2023

Monoclonal antibodies are gaining attention as alternative or additive treatments for atopic dermatitis. Lebrikizumab is a new and investigational monoclonal antibody designed to selectively inhibit IL-13. “In Most TEAEs were mildly or moderately severe and resulted in a low frequency of treatment discontinuation.

Dermatology 97

Dermatology Antibody Clinical Trials Clinical Trials 97

Pharmaceutical Technology

MAY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Life Science 162

Life Science DNA Antibody Development 162

Drug Discovery World

MARCH 13, 2024

With government support and strong academic institutions, does Singapore have what it takes to become a global centre for life sciences? DDW’s Diana Spencer explores how the country is turning pioneering science into a successful biotech industry.

Life Science 69

Life Science Genome Genomics Research 69

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

XTalks

AUGUST 16, 2022

The new COVID-19 booster was approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a booster dose for “active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older,” Moderna outlined in a news release.

Vaccination 98

Vaccination Vaccine Antibody Regulation 98

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. In June 2022, the European Medicines Agency approved an adeno-associated viral (AAV) vector-based therapy for adults with Hemophilia A, making the treatment available to an estimated 3,200 eligible patients. [1] CEVEC became part of Cytiva in October 2022.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

APRIL 28, 2023

Macrophages suppress natural killer cells in lung cancer tumours Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer.

Drugs 52

Drugs Life Science Clinical Trials Clinical Trials 52

pharmaphorum

JULY 25, 2022

Vabysmo (faricimab) has been recommended by the EMA’s human medicines committee as a treatment for neovascular or wet age-related macular degeneration (AMD) and diabetic macular oedema (DME), so could be fully approved and ready to roll out in the next few months, subject to pricing and reimbursement negotiations.

Drugs 72

Drugs Antibody Medicine Marketing 72

XTalks

JANUARY 26, 2023

XTALKS WEBINAR: Review of Key Trends for Life Science Commercial Teams in 2023 Register for this free on-demand webinar to learn about the latest trends in sales and marketing campaigns that could help bolster commercial success for life science companies this year. percent vs 72.9

FDA Approval 97

FDA Approval Life Science Clinical Trials Clinical Trials 97

XTalks

MAY 24, 2024

Carbone, professor of internal medicine and director of the James Thoracic Oncology Center at the Ohio State University Medical Center, in a recent press release. Imdelltra is a novel immunotherapy, where a bispecific antibody binds to both CD3 on T cells and DLL3 on tumor cells.

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

XTalks

JUNE 8, 2022

Amgen’s Riabni, a CD20-directed cytolytic antibody and biosimilar to Rituxan, got approval from the FDA on Monday for adults with moderate to severe rheumatoid arthritis. B-cell targeted therapy with the monoclonal antibody Rituxan (rituximab) is used to treat RA. million Americans. Evidence for the Efficacy of Riabni.

FDA Approval 96

FDA Approval Antibody Clinical Trials Clinical Trials 96

XTalks

OCTOBER 12, 2021

The research team, led by Dr. Ritu Chakravarti, assistant professor in the UToledo College of Medicine and Life Sciences, and the paper’s lead author, was investigating 14-3-3? antibodies in the knockout (KO) rats. antibody levels, collagen production, reduced joint inflammation and maintained bone quality.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

Pharmaceutical Technology

APRIL 18, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Protein 147

Protein Vaccination Vaccine Production 147

Drug Discovery World

MAY 11, 2023

Fundraising and investment are a core pillar of not just BioTrinity events but of the drug discovery industry at large, so events such as Tuesday’s keynote, Investment Trends for the Life Sciences Industry, are critical for members of the industry.

Life Science 52

Life Science Genetics Vaccination Vaccine 52

Drug Discovery World

JANUARY 9, 2024

2024 is anticipated to be a transformational year for the pharma industry, with new modalities like antibody drug conjugates and AI/machine learning providing therapies for patients with limited treatment options. The 2024 Drugs to Watch, are: 1. Due to a delayed US launch it remains a drug to watch for 2024.

Drugs 69

Drugs Antibody Gene Editing Medicine 69

pharmaphorum

NOVEMBER 22, 2022

It also says it will focus on technological areas where it has strength, such as antibody-drug conjugates. Those two drugs are billed as Merck ‘wave 2’ medicines, building on a first wave of recent launches, including PD-1 inhibitor Bavencio (avelumab), Mavenclad (cladribine) for MS and lung cancer therapy Tepmetko (tepotinib).

Production 52

Production Licensing Licensing Antibody 52

pharmaphorum

JANUARY 25, 2022

The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving reagent and antibody selection to help scientists run more successful experiments, drawing on data from published studies and organisations’ internal databases.

Life Science 52

Life Science Pharma Companies Reagent Scientist 52

XTalks

AUGUST 18, 2023

Both are bispecific antibodies, administered as subcutaneous infusions, that directly engage CD3+ T cells to target cancer cells that express BCMA. Multiple myeloma is an aggressive blood cancer that affects plasma cells, which make antibodies that help the immune system fight infections.

FDA Approval 98

FDA Approval Drugs Antibody Trials 98

XTalks

MARCH 28, 2024

Furthermore, the introduction of multi-targeted kinase inhibitors and monoclonal antibodies is also being examined as a possible form of therapy. Building Cancer Awareness and Empowering Métis Youth: Featuring Jordyn Playne, President, Métis Nation of Ontario Youth Council – Xtalks Life Science Podcast Ep.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

Drug Discovery World

MAY 22, 2023

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. However, the fundamental dynamic underpinning these companies remains: they need each other in order to keep pipelines producing innovative medicines.”

RNA 52

RNA Pharma Companies Antibody Life Science 52

XTalks

JULY 10, 2023

UCB specializes in the discovery and development of innovative medicines for severe diseases that affect the immune system or central nervous system. Rystiggo (rozanolixizumab) is a medication indicated for the treatment of gMG in adult patients who test positive for AChR or MuSK antibodies. What Is Generalized Myasthenia Gravis (gMG)?

FDA Approval 98

FDA Approval Antibody Protein Engineer 98

Drug Discovery World

JULY 11, 2023

Tim Lowery , President, JSR Life Sciences, asks whether artificial intelligence can do for life sciences what it has done in other sectors and whether these tools can keep up with the complexities of human biology. So, where do we go from here to realise their potential in life sciences?

Big Data 40

Big Data Development Life Science Drugs 40